Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran

MR. Aflatoonian, I. Sharifi, B. Aflatoonian, M. Bamorovat, A. Heshmatkhah, Z. Babaei, P. Ghasemi Nejad Almani, MA. Mohammadi, E. Salarkia, A. Aghaei Afshar, H. Sharifi, F. Sharifi, A. Khosravi, M. Khatami, N. Arefinia, A. Fekri, S. Farajzadeh, A....

. 2019 ; 13 (6) : e0007423. [pub] 20190612

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044763

BACKGROUND: The control of cutaneous leishmaniasis (CL) is facilitated by knowledge of factors associated with the treatment failures in endemic countries. The aim of this evaluation was to identify the potential risk determinants which might affect the significance of demographic and clinical characteristics for the patients with anthroponotic CL (ACL) and the outcome of meglumine antimoniate (MA) (Glucantime) treatment. METHODOLOGY/PRINCIPAL FINDINGS: This current was executed as a cohort spanning over a period of 5 years which centered in southeastern part of Iran. Altogether, 2,422 participants were evaluated and 1,391 eligible volunteer patients with ACL caused by Leishmania tropica were included. Overall, 1,116 (80.2%) patients received MA intraleisionally (IL), once a week for 12 weeks along with biweekly cryotherapy, while 275 (19.8%) patients received MA alone (20 mg/kg/day for 3 weeks) (intramuscular, IM). The treatment failure rate in ACL patients was 11% using IL combined with cryotherapy plus IM alone, whilst 9% and 18.5% by IL along with cryotherapy or IM alone, respectively. Multivariate logistic regression model predicted 5 major associated-risk determinants including male (odds ratio (OR) = 1.54, confidence interval (CI) = 1.079-2.22, p = 0.018), lesion on face (OR = 1.574, CI = 1.075-2.303, p = 0.02), multiple lesions (OR = 1.446, CI = 1.008-2.075, p = 0.045), poor treatment adherence (OR = 2.041, CI = 1.204-3.46, p = 0.008) and disease duration > 4 months (OR = 2.739, CI = 1.906-3.936, p≤0.001). CONCLUSIONS/SIGNIFICANCE: The present study is the original and largest cohort of ACL patients who treated with MA. A comprehensive intervention and coordinated action by the health authorities and policy-makers are crucial to make sure that patients strictly follow medical instructions. Early detection and effective therapy < 4 months following the onset of the lesion is critical for successful treatment of the patients. Since a significant number of patients are still refractory to MA, reducing man-vector exposure and development of new effective alternative drugs are essential measures against ACL due to L. tropica.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044763
003      
CZ-PrNML
005      
20200116110544.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pntd.0007423 $2 doi
035    __
$a (PubMed)31188834
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Aflatoonian, Mohammad Reza $u Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
245    10
$a Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran / $c MR. Aflatoonian, I. Sharifi, B. Aflatoonian, M. Bamorovat, A. Heshmatkhah, Z. Babaei, P. Ghasemi Nejad Almani, MA. Mohammadi, E. Salarkia, A. Aghaei Afshar, H. Sharifi, F. Sharifi, A. Khosravi, M. Khatami, N. Arefinia, A. Fekri, S. Farajzadeh, A. Khamesipour, M. Mohebali, MM. Gouya, MR. Shirzadi, RS. Varma,
520    9_
$a BACKGROUND: The control of cutaneous leishmaniasis (CL) is facilitated by knowledge of factors associated with the treatment failures in endemic countries. The aim of this evaluation was to identify the potential risk determinants which might affect the significance of demographic and clinical characteristics for the patients with anthroponotic CL (ACL) and the outcome of meglumine antimoniate (MA) (Glucantime) treatment. METHODOLOGY/PRINCIPAL FINDINGS: This current was executed as a cohort spanning over a period of 5 years which centered in southeastern part of Iran. Altogether, 2,422 participants were evaluated and 1,391 eligible volunteer patients with ACL caused by Leishmania tropica were included. Overall, 1,116 (80.2%) patients received MA intraleisionally (IL), once a week for 12 weeks along with biweekly cryotherapy, while 275 (19.8%) patients received MA alone (20 mg/kg/day for 3 weeks) (intramuscular, IM). The treatment failure rate in ACL patients was 11% using IL combined with cryotherapy plus IM alone, whilst 9% and 18.5% by IL along with cryotherapy or IM alone, respectively. Multivariate logistic regression model predicted 5 major associated-risk determinants including male (odds ratio (OR) = 1.54, confidence interval (CI) = 1.079-2.22, p = 0.018), lesion on face (OR = 1.574, CI = 1.075-2.303, p = 0.02), multiple lesions (OR = 1.446, CI = 1.008-2.075, p = 0.045), poor treatment adherence (OR = 2.041, CI = 1.204-3.46, p = 0.008) and disease duration > 4 months (OR = 2.739, CI = 1.906-3.936, p≤0.001). CONCLUSIONS/SIGNIFICANCE: The present study is the original and largest cohort of ACL patients who treated with MA. A comprehensive intervention and coordinated action by the health authorities and policy-makers are crucial to make sure that patients strictly follow medical instructions. Early detection and effective therapy < 4 months following the onset of the lesion is critical for successful treatment of the patients. Since a significant number of patients are still refractory to MA, reducing man-vector exposure and development of new effective alternative drugs are essential measures against ACL due to L. tropica.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antiprotozoální látky $x terapeutické užití $7 D000981
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kohortové studie $7 D015331
650    _2
$a kryoterapie $x metody $7 D017679
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a Leishmania tropica $x izolace a purifikace $7 D007895
650    _2
$a leishmanióza kožní $x farmakoterapie $x epidemiologie $x mikrobiologie $7 D016773
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meglumin antimoniát $x terapeutické užití $7 D000077485
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rizikové faktory $7 D012307
650    _2
$a neúspěšná terapie $7 D017211
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Írán $x epidemiologie $7 D007492
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sharifi, Iraj $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Aflatoonian, Behnaz $u Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Bamorovat, Mehdi $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Heshmatkhah, Amireh $u Shahid Dadbin Clinic, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Babaei, Zahra $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Ghasemi Nejad Almani, Pooya $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Mohammadi, Mohammad Ali $u Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences٫ Kerman, Iran.
700    1_
$a Salarkia, Ehsan $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Aghaei Afshar, Abbas $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Sharifi, Hamid $u HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Sharifi, Fatemeh $u Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Khosravi, Ahmad $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Khatami, Mehrdad $u School of Medicine, Bam University of Medical Sciences, Bam, Iran.
700    1_
$a Arefinia, Nasir $u Shahid Dadbin Clinic, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Fekri, Alireza $u Department of Dermatology, Afzalipour Hospital, Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Farajzadeh, Saeideh $u Department of Dermatology, Afzalipour Hospital, Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Khamesipour, Ali $u Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
700    1_
$a Mohebali, Mehdi $u Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
700    1_
$a Gouya, Mohammad Mehdi $u Center of Disease Control (CDC), Ministry of Health, Tehran, Iran.
700    1_
$a Shirzadi, Mohammad Reza $u Center of Disease Control (CDC), Ministry of Health, Tehran, Iran.
700    1_
$a Varma, Rajender S $u Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, Czech Republic.
773    0_
$w MED00165375 $t PLoS neglected tropical diseases $x 1935-2735 $g Roč. 13, č. 6 (2019), s. e0007423
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31188834 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200116110918 $b ABA008
999    __
$a ok $b bmc $g 1483032 $s 1083436
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 13 $c 6 $d e0007423 $e 20190612 $i 1935-2735 $m PLoS neglected tropical diseases $n PLoS negl. trop. dis. $x MED00165375
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace